Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug SubstancePhio Pharmaceuticals Corp. (
NASDAQ: PHIO) today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next stage of clinical development.
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug SubstanceKing of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company developing...
OTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On DemandView presentations from European and Canadian public growth companies following the October 7–8 event
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio’s INTASYL® siRNA therapeutic platform at The Global Markets Virtual Forum hosted by www.VirtualInvestorConferences.com (VIC) on October 8th, 2026.
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.com
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd ConferencePhio Pharmaceuticals Corp. (
NASDAQ: PHIO) today announced that it has accepted the invitation to present at the National Investment Banking Association’s (NIBA) 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida.
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd ConferenceKing of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 ConferencePhio Pharmaceuticals Corp. (
NASDAQ: PHIO) today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania.
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 ConferenceKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceKing of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO), a clinical-stage biotechnology company developing...
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business UpdateStrategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of DirectorsKing of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant DecisionKing of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand ViewingNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in...
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25thCompany Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesKing of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (
NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
